转移性去势抵抗性前列腺癌中177镥-前列腺特异性膜抗原配体治疗的现实世界结局与预测性生物标志物:欧洲泌尿外科学会青年泌尿学家前列腺癌工作组多机构观察性研究
该研究为回顾性观察性研究,纳入8个欧洲中心的233例转移性去势抵抗性前列腺癌患者,评估177Lu PSMA-617治疗的真实世界表现及预测生物标志物。结果显示,前两个周期后PSA下降≥30%是早期应答标志,PSA倍增时间>6个月及基线GGT≤31 U/L与应答或进展风险相关。
要点
- 前两个周期后PSA下降≥30%与治疗应答显著相关,可作为早期应答标志。
- PSA倍增时间>6个月与治疗应答显著相关。
- 基线GGT≤31 U/L与无内脏转移患者进展风险升高1.5倍相关。
核心结论
- 177Lu PSMA-617在真实世界mCRPC患者中是一种有效的治疗选择。
- 前两个周期后PSA下降≥30%是易于临床实施的早期应答标志。
研究设计与样本
- 回顾性观察性研究,纳入8个欧洲高容量中心的233例接受177Lu PSMA治疗的mCRPC患者。
主要发现
- 第一个、第二个、第三个治疗周期后PSA下降≥30%的患者比例分别为41.7%、63.5%、77.8%。
- PSMA PET-CT再分期显示33.7%的患者达到影像学应答,包括2例完全缓解,13.4%为疾病稳定。
- 中位进展时间为5个月,至开始后续抗肿瘤治疗的中位时间为8.5个月。
- 前两个周期后PSA下降≥30%(第1周期:p=0.0003;第2周期:p=0.004)、前三个周期后绝对PSA(第1周期:p=0.011;第2周期:p=0.0005;第3周期:p=0.002)及PSA倍增时间>6个月(p=0.009)与治疗应答显著相关。
- 基线GGT≤31 U/L与无内脏转移患者进展风险升高1.5倍相关,有内脏转移患者中未观察到该关联(p=0.046)。
临床怎么用
- 作者认为前两个周期后PSA下降≥30%可作为临床实践中的早期应答标志,用于个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Association of Urology guidelines include the lutetium-177 (177Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for metastatic castration-resistant prostate cancer (mCRPC). A major challenge in clinical practice is to pursue a personalized treatment approach based on robust predictive biomarkers. OBJECTIVE: To assess the performance of 177Lu PSMA in real-world practice and to elaborate clinical biomarkers for evaluating treatment responses. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective observational study including 233 patients with mCRPC treated with 177Lu PSMA in eight high-volume European centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline characteristics and clinical parameters during and after 177Lu PSMA treatment were documented. Correlations to treatment response were analyzed using χ2 and log-rank tests, with differences between groups with and without disease progression calculated using a Mann-Whitney U test. Univariate and multivariate-adjusted hazard ratios (HRs) were measured using Cox proportional hazards models. RESULTS AND LIMITATIONS: A prostate-specific antigen (PSA) decrease of ≥30% was observed in 41.7%, 63.5%, and 77.8% of patients after the first, second, and third treatment cycle, respectively. Restaging performed via PSMA positron emission tomography-computed tomography revealed that 33.7% of patients had an imaging-based response, including two patients with a complete response, while 13.4% had stable disease. The median time to progression was 5 mo and the median time until the start of a consecutive antineoplastic therapy was 8.5 mo. Of importance, a PSA decrease ≥30% after the first two cycles of 177Lu PSMA (1 cycle: p = 0.0003; 2 cycles: p = 0.004), absolute PSA after the first three cycles (1 cycle: p = 0.011; 2 cycles: p = 0.0005; 3 cycles: p = 0.002), and a PSA doubling time >6 mo (p = 0.009) were significantly correlated to treatment response. Furthermore, gamma-glutamyl transferase ≤31 U/L at the start of 177Lu PSMA therapy was correlated with 1.5 times higher risk of progression for patients without but not with visceral metastases (p = 0.046). CONCLUSIONS: 177Lu PSMA is an effective treatment option in mCRPC in the real-world setting. A PSA decrease ≥30% after the first two cycles is an early marker of response that can be easily implemented in clinical practice. PATIENT SUMMARY: 177Lu PSMA is a radioactive agent approved for treatment of advanced prostate cancer. We reviewed its use outside of clinical trials for patients treated at eight European centers. We found that 177Lu PSMA is an effective treatment option in real-world practice. A PSA (prostate-specific antigen) decrease of ≥30% after the first two therapy cycles is an early indicator of response to treatment and can be used in personalizing treatments for patients.
引用
- Kafka M, Horninger A, di Santo G, et al. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study. Eur Urol Oncol. 2023. PMID: 37604763. doi:10.1016/j.euo.2023.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。